On Tuesday, OpenAI revealed its acquisition of a four-year-old AI biotech software firm named Orchestra Bio, according to a statement on its website. The specifics of the agreement were not made public, but it has been reported that the startup secured approximately $20 million in funding by 2025 from investors such as Andreessen Horowitz, Atria, and 8VC.

Orchestra develops AI agents designed to assist biotech firms in managing the details of drug discovery processes, including financial tracking and addressing scheduling conflicts related to clinical trials.

According to OpenAI, the Orchestra team and its technology will be integrated to enhance Rosalind, its AI model focused on life sciences research, along with its associated Rosalind Workbench tool, which aims to aid researchers in experiment planning and result analysis. OpenAI has already attracted prominent clients for Rosalind, including Moderna⁠ and Novo Nordisk⁠.

This acquisition illustrates how the leading AI organizations (particularly OpenAI and Anthropic) are continuously developing software for major sectors like pharmaceuticals. Within the startup community, there is a persistent concern that the labs might roll out new features at any moment, becoming direct competitors. In this instance, Orchestra is being integrated rather than eliminated.